Shots:

• The P-III (ADhere) study evaluates lebrikizumab + TCS vs PBO + TCS in 211 adult & adolescent patients aged 12 to ≤18yrs. with AD
• The trial met all 1EPs & 2EPs i.e., 70% of patients achieved 75% improvement in overall disease severity (EASI-75), 41% vs 22% achieved clear or almost clear skin (IGA) @16wks., (70% vs 42%) achieved an EASI-75 response, improvements across 2EPs including skin clearance, itching, interference of itch on sleep, & QoL measures
• The safety results were consistent with prior lebrikizumab studies & reported a higher frequency of AEs (43% vs 35%). Additionally, Lilly has exclusive rights to develop & commercialize lebrikizumab in the US & ROW (Ex-EU)

Ref: PR Newswire | Image: Lilly